Precision engineered novel disease treatments
Drug candidates with unique properties, engineered atom by atom
The result of two decades of scientific advances
2 to 4 chemically diverse novel clinical candidates per program
Generated by the world's most advanced drug design & development platform—bar none
Changing the standard of care— for every disease we address
7 drug programs, 14 candidates—and counting . . .
Cardiovascular Disease
First-in-class Precision Oral Anticoagulants (PROACS) for currently unserved patients who need lifelong anticoagulant-antiplatelet dual therapy
Diabetic Vision Loss
First oral prophylactic in development for the prevention of progressive vision loss in diabetics
Hereditary Angioedema
Safe oral prophylactic for treatment of chronic nonallergic swelling from a rare but potentially life-threatening disease that can block airways and cause asphyxiation
Cancer–Program 1
Novel chemotherapy agents effective against multidrug-resistant tumors
Cancer–Program 2
Novel immuno oncology agents targeting gastric, renal, ovarian and other cancers that mask their presence from the immune system by overproducing adenosine in the extracellular tumor microenvironment
Cancer–Program 3
Anti-tumor drugs that prevent metastasis in highly aggressive breast, ovary, uterus, prostate, colon, cervix, skin, and other cancers
Metabolic Disorder
Treatments for the most serious form of nonalcoholic fatty liver disease